Efavirenz + Emtricitabine + TDF

Efavirenz + Emtricitabine + TDF

Form: Tablet

Strength: 600/200/300 mg

Reference Brands: Atripla(US/EU)

Category: Anti Viral

Atripla Tablets combine Efavirenz (600 mg), Emtricitabine (200 mg), and Tenofovir Disoproxil Fumarate (300 mg) in a once-daily, fixed-dose antiretroviral therapy for HIV-1 infection. Widely recommended in global HIV treatment guidelines, Atripla simplifies adherence and improves patient outcomes. On PharmaB2B platforms, global pharmaceutical buyers, NGOs, and procurement agencies can source WHO-GMP and USFDA-approved Atripla formulations from trusted manufacturers. Ideal for tender supply, HIV programs, and institutional purchases, Atripla is available for bulk export at competitive prices. Partner with verified suppliers on PharmaB2B to ensure timely, compliant delivery of high-quality antiretrovirals essential for public health programs.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Zanamivir

Strength: 5 mg/blister

Form: Inhalation powder

Reference Brands: Relenza(EU & US)

View Details Get Enquiry
Oseltamivir Phosphate Capsule

Strength: Capsule- 30 mg, 45 mg, 75 mg; Oral Suspension - 6 mg/mL (reconstituted)

Form: Capsules and Oral solution

Reference Brands: Tamiflu(EU & US)

View Details Get Enquiry
Amantadine

Strength: Tab -100 mg; Capsule- 100 mg; Oral solution - 50 mg/5 mL; Extended-release capsule (ER) - 129 mg, 193 mg

Form: Tablet; Capsule; Oral Solution and ER Capsule

Reference Brands: Symmetrel(EU & US); Osmolex ER(US), Gocovri(US)

View Details Get Enquiry
Glecaprevir + Pibrentasvir

Strength: Glecaprevir- 100 mg + Pibrentasvir - 40 mg

Form: Tablet

Reference Brands: Mavyret (US); Maviret (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.